Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

This phase II trial studies whether the nonavalent human papillomavirus vaccine given to
adults prior to kidney transplantation can help the body build and maintain an effective
immune response during the post-transplant period when they receive immunosuppressive drugs
to prevent transplant rejection. This study will help inform our scientific understanding
about vaccine-induced immune responses among immunosuppressed individuals.

Intervention

Laboratory Biomarker Analysis, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine

Condition

Human Papillomavirus Infection

Investigators

Marc T Goodman

See list of participating sites